e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Diffuse parenchymal lung disease I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model
T. Samukawa, T. Hamada, T. Kumamoto, G. Tsukuya, S. Kubota, M. Watanabe, H. Inoue (Kagoshima, Japan)
Source:
Annual Congress 2013 –Diffuse parenchymal lung disease I
Session:
Diffuse parenchymal lung disease I
Session type:
Thematic Poster Session
Number:
2348
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Samukawa, T. Hamada, T. Kumamoto, G. Tsukuya, S. Kubota, M. Watanabe, H. Inoue (Kagoshima, Japan). Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model. Eur Respir J 2013; 42: Suppl. 57, 2348
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016
The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
A role of Foxc2 gene in mice with bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Thymosin beta4 protects mice from bleomycin-induced damage in the lung
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation
versus
fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 396s
Year: 2006
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Temporal profile of metaloproteases gene expression in elastase-induced emphysema
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
The role of expression of TLR 4 in bleomycin-induced pulmonary fibrosis in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Difference in the dynamic state between SP-A and SP-D in the IPF lung
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Quantitation of hydroxyproline in a mouse model of bleomycin-induced lung fibrosis: comparison with histological analysis
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept